U.S. Markets open in 5 hrs 55 mins

Personalis, Inc. (PSNL)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.1700+0.2900 (+7.47%)
At close: 04:00PM EST
4.1300 -0.04 (-0.96%)
After hours: 07:52PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.8800
Bid0.0000 x 800
Ask0.0000 x 900
Day's Range3.8000 - 4.2200
52 Week Range1.7300 - 12.9600
Avg. Volume539,515
Market Cap191.701M
Beta (5Y Monthly)1.56
PE Ratio (TTM)N/A
EPS (TTM)-1.3760
Earnings DateFeb 22, 2023 - Feb 27, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.60
  • Insider Monkey

    15 Worst Stock Picks of Cathie Wood in 2022

    In this piece, we will take a look at the 15 worst stock picks of Cathie Wood in 2022. For her top five worst stock picks, head on over to 5 Worst Stock Picks of Cathie Wood in 2022. Cathie Wood is one of the more popular hedge fund investors when it comes to the […]

  • Business Wire

    Personalis to Participate at Upcoming Investor Conferences

    FREMONT, Calif., February 06, 2023--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the following investor conferences:

  • Benzinga

    Analyst Upgrades Personalis; Says Biopharma Is Strong, Cash Burn Is Down

    Needham has upgraded Personalis Inc (NASDAQ: PSNL) to Buy from Hold with a price target of $8. The analyst writes that Personalis's cash burn has likely peaked and expects it to decline steadily over the next few years. Needham writes that PSNL used $41 million of cash in 3Q22, up from $33 million in 2Q22, and a significant portion of its new facility expenses ($38 million in 2022) fell into 3Q22. The company used $121 million in 2022, up from $78 million in 2021 (down from its initial expectati